THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, November 18, 2022
Collaborating with CROs will help pharmaceutical companies leverage their capabilities, accelerate innovation and drug development, and tackle pressing concerns.
FREMONT, CA: A contract research organisation (CRO) helps companies worldwide with research and development, leveraging expertise in cell-based assays, immunogenicity, biomarkers, and pharmacokinetics. They are hired to provide research support and conduct clinical trials to safely and efficiently bring life-saving drugs and vaccines to market.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
CROs perform assay development and validation, sample analysis, lot release testing, and ongoing data surveillance after drug products are introduced to the market. Furthermore, CROs reduce drug development timelines and costs. These features also represent the larger-scale trend of pharma companies outsourcing R&D to CROs specialising in state-of-the-art technologies and expertise.
It takes years to bring a drug product to market, from research to final drug approval. Developing a new medicine costs about 2.6 billion USD on average, including the failure costs. However, only a few new drug candidates in clinical trials are ultimately approved. Today, many drug developers turn to contract research organisations as it offers various benefits.
Reduce Expenditures
Outsourcing is a risk reduction strategy. Pharmaceutical companies have witnessed a considerable decline in profits in recent years. Working with a CRO has numerous benefits, from reducing or minimising the need to hire research staff, investing in in-house infrastructure for R&D and manufacturing, and managing an ambiguous success potential. It increases success rates and accelerates drug discovery and development, potentially leading to higher profits.
Deals Increasingly Complex Drugs and Clinical Trials
Advancements in cell and gene therapies, antibody-drug conjugates, products using cytotoxic compounds, and in vitro and in vivo processing methods have made drug development more complex. CROs bridge the gap of innovation lack in pharma. Many continuously develop and improve technologies to provide sample analysis and assay validation, while others release testing before manufacturing with a commitment to the highest performance standards, accuracy, and efficiency.
Reduce Time to Market
CROs possess the skills and infrastructure to provide critical services at a higher efficiency level. They can modify drug candidates in real-time based on the data amassed during clinical studies. Shortened lead times allow pharmaceutical firms to observe a return on their products much sooner, as a range of complexities is managed at every development stage by organisations built on services addressing these.
With these advantages, CRO support improves pharma R&D. R&D outsourcing has become a global phenomenon that will remain. Pharma companies and CROs have joined forces to optimise their greatest capabilities, accelerate innovation and drug development, and address pressing concerns such as the pandemic.
More in News